



Attorney Docket # 4830-13PUS

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Pericles CALIAS et al.

Serial No.: 10/511,373

Filed: October 14, 2004

For: Cross-Linked Hyaluronate Compounds

Examiner:

Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 13, 2005  
(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

Signature

July 13, 2005  
Date of Signature

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

S I R:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.


It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b),

or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By:   
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: July 13, 2005



Under the Supermarket Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/511,373
Filing Date	October 14, 2004
First Named Inventor	Pericles CALIAS
Art Unit	
Examiner Name	
Attorney Docket Number	4830-13PUS

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind-Code <sup>2</sup> (if known)			
/J.L./		US-3,338,885	08/29/1967	Coker et al.	
/J.L./		US-3,376,263	04/02/1968	Ishida et al.	
/J.L./		US-3,468,818	09/23/1969	Phillips	
/J.L./		US-3,828,024	08/06/1974	Breslow	
/J.L./		US-5,614,595	03/25/1997	Bender et al.	
/J.L./		US-6,723,709	04/20/2004	Pressato et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>2</sup> Kind-Code <sup>5</sup> (if known)				
/J.L./		GB1211553	11/11/1970	Lubowitz et al.		
/J.L./		DE1270287	09/27/1965	Manecke et al.	Abstract	
/J.L./		DE1243687	12/28/1967	Bestain et al.	Abstract	
/J.L./		SU1723125	03/30/1992	Vasileva	Abstract	

Examiner Signature	/Jonathan Lau/	Date Considered	06/15/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PAT-9100 (1-800-786-9100) and select option 2



Submittable for Form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3


## Complete if Known

Application Number	10/511,373
Filing Date	October 14, 2004
First Named Inventor	Pericles CALIAS
Art Unit	
Examiner Name	
Attorney Docket Number	4830-13PUS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.L./		W. McCoull et al., "Recent Synthetic Applications of Chiral Aziridines", <i>Synthesis</i> 2000, No. 10, pp. 1347-1365.	
/J.L./		G. Sosnovsky et al., "In the Search for New Anticancer Drugs. VII", <i>J Cancer Res Clin Oncol</i> No 107(3), pp. 217-220 (1984).	
/J.L./		S. Nishimoto et al., "1.1'-(2.6-Naphthalenedicarbonyl) diaziridine as a Useful Agent for Photocrosslinking of Poly(4-Hydroxystyrene) in Film", <i>Journal of Polymer Science: Polymer Letters Edition</i> , Vol. 22, pp. 323-326 (1984)	
/J.L./		W. Tsuji et al., "Properties of Acrylic Acid Grafted Polypropylene Fiber", <i>Bull. Inst. Chem. Res.</i> , Vol. 50, No. 2 (1972).	
/J.L./		Ikeda et al., "Improvement of Crease Resistance of Cotton Fabric by the Grafting with Acrylic Acid and Aftertreatment with Tris (1-Aziridinyl) Phosphine Oxide", <i>Sim'l Gakkaishi</i> , No. 30 (5-6), pp. T292-T298 (1974).	
/J.L./		Larsen et al., "Biocompatibility of Hyaluron Polymers in Various Tissue Compartments", <i>Materials Research Society Symp. Proc.</i> , No. 394, pp. 149-153 (1995).	
/J.L./		T. Pouyani et al., "Functionalized Derivatives of Hyaluronic Acid Oligosaccharides: Drug Carriers and Novel Biomaterials", <i>Bioconjugate Chem.</i> , Vol. 5, pp. 339-347 (1994)	
/J.L./		T. Laurent et al., "Cross-linked Gels of Hyaluronic Acid", <i>Acta Chem Scand.</i> , Vol. 18, No. 1, p. 274 (1964)	
/J.L./		N. Yui et al., "Regulated release of drug microspheres from inflammation responsive degradable matrices of crosslinked hyaluronic acid", <i>Journ. of Controlled Release</i> , Vol. 25, pp. 133-143 (1993)	
/J.L./		N. Yui et al., "Inflammation responsive degradation of crosslinked hyaluronic acid gels", <i>Journ. Of Controlled Release</i> , Vol. 22, p.105-116 (1992).	
Examiner Signature	/Jonathan Law/		Date Considered 06/15/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



/J.L./	A.M. Patti et al., "Effect of hyaluronic acid on human chondrocyte cell lines from articular cartilage", <i>Tissue &amp; Cell</i> , Vol. 33(3), pp. 294-300 (2001)	
/J.L./	Gabriel Herrero-Beaumont et al., "Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee", <i>Clinica Chimica Acta</i> , Vol. 308, pp. 107-115 (2001)	
/J.L./	P. Andersson et al., "Enantioselective Addition of Organolithium Reagents to Imines Mediated by C <sub>2</sub> -Symmetric Bis(aziridine) Ligands, <i>Tetrahedron</i> 54, pp 11549-11566 (1998)	
/J.L./	D. Tanner et al., "Asymmetric Catalysis via Chiral Aziridines", <i>Acta Chemica Scandinavia</i> , Vol. 50, No. 4, pp. 361-368 (1996).	
/J.L./	Denmark et al., "Preparation of Chiral Bisoxazolines: Observations on the Effect of Substituents", <i>J. Org. Chem.</i> , Vol. 60, pp. 4884-4892 (1995)	
/J.L./	G. Manecke et al., "Amphotere ion exchanger", <i>Die Makromolekulare Chemie</i> , Vol. 175, pp. 1833-1845 (1974)	
/J.L./	Kadorkina et al., <i>Izv. Akad. Nauk SSSR Ser. Khim.</i> 4, pp. 882-885 (1991) abstract	
/J.L./	Watanabe et al., "Synthesis of Aziridine Derivatives from Unsaturated Carboxylic Acid Halides or Chloroformates an Aziridine", <i>Kogyo Kagaku Zasshi</i> , Vol. 72 (6) pp. 1349-1352 (1969)	
/J.L./	Vercruyse et al., "Hyauronate Derivatives in Drug Delivery", <i>Critical Reviews<sup>TM</sup> in Therapeutic Drug Carrier Systems</i> , No. 15(5), pp. 513-555 (1998).	
/J.L./	L. Freed et al., "Biodegradable Polymer Scaffolds for Tissue Engineering", <i>Bio/Technology</i> , Vol. 12, pp. 689-693 (1994).	
/J.L./	R. Sparer et al., "Controlled Release from Glycosaminoglycan Drug Complexes", Chapter 6, pp. 107-119 (1983)	
/J.L./	L. Pape et al., "The use of Sodium Hyaluronate (Healon®) in Human Anterior Segment Surgery", <i>Ophthalmology</i> , Vol. 87(7), pp. 698-705 (1980).	

Examiner Signature	/Jonathan Lau/	Date Considered	06/15/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-9100 (1-800-786-9100) and select option 2